Clinical Cancer Research  Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shimizu, M.
Right arrow Articles by Weinstein, I. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shimizu, M.
Right arrow Articles by Weinstein, I. B.
Clinical Cancer Research Vol. 11, 2735-2746, April 2005
© 2005 American Association for Cancer Research


Cancer Therapy: Preclinical

(–)-Epigallocatechin Gallate and Polyphenon E Inhibit Growth and Activation of the Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor-2 Signaling Pathways in Human Colon Cancer Cells

Masahito Shimizu1,2, Atsuko Deguchi1, Jin T.E. Lim1, Hisataka Moriwaki2, Levy Kopelovich3 and I. Bernard Weinstein1

Authors' Affiliations: 1 Herbert Irving Comprehensive Cancer Center and Department of Medicine, Columbia University Medical Center, New York, New York; 2 Department of Medicine, Gifu University School of Medicine, Gifu, Japan; and 3 Division Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland

Requests for reprints: I. Bernard Weinstein, Herbert Irving Comprehensive Cancer Center and Department of Medicine, Columbia University Medical Center, HHSC-1509, 701 West 168 Street, New York, NY 10032-2704. Phone: 212-305-6921; Fax: 212-305-6889; E-mail: ibw1{at}columbia.edu.

Purpose: (–)-Epigallocatechin gallate (EGCG) inhibits activation of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2) and multiple downstream signaling pathways in cancer cell lines. In this study we compared the cellular and molecular effects of EGCG with a well-standardized decaffeinated green tea catechin mixture Polyphenon E (Poly E) on human colon cancer cell lines.

Experimental Design and Results: Both EGCG and Poly E preferentially inhibited growth of the Caco2, HCT116, HT29, SW480, and SW837 colon cancer cells when compared with the FHC normal human fetal colon cell line. The EGFR and HER2 proteins were overexpressed and constitutively activated in all of the colon cancer cell lines when compared with the FHC cell line. Treatment of HT29 cells with EGCG or Poly E caused an increase of cells in G1 and induced apoptosis. Both EGCG and Poly E caused a decrease in the phosphorylated forms of EGFR and HER2 proteins, and subsequently caused a decrease in the phosphorylated forms of the extracellular signal-regulated kinase and Akt proteins. Similar effects of these compounds were seen when the cells were stimulated with transforming growth factor {alpha}. Reporter assays indicated that both EGCG and Poly E inhibited the transcriptional activity of the activator protein 1 (AP-1), c-fos, nuclear factor {kappa}B, and cyclin D1 promoters. The combination of only 1 µg/mL of epicatechin plus 10 µg/mL of EGCG displayed synergistic effects on growth inhibition and induction of apoptosis. Furthermore, when treatment was prolonged for 96 hours, 1 µg/mL of EGCG or Poly E was sufficient to inhibit growth, reduce activation of EGFR and HER2, and induce apoptosis.

Conclusion: Our findings suggest that EGCG or Poly E may be useful in the chemoprevention and/or treatment of colon cancer. Poly E contains about 60% EGCG, yet pure EGCG and Poly E had similar potencies (expressed as µg/ml). Poly E may be preferable because it is easier to prepare and this mixture of catechins may exert synergistic effects.

Key Words: Colon Cancer Cells • EGCG • Polyphenon E • EGFR/HER2 • Mitogen-activated protein kinase




This article has been cited by other articles:


Home page
Cancer Prevention ResearchHome page
M. Shimizu, Y. Shirakami, H. Sakai, S. Adachi, K. Hata, Y. Hirose, H. Tsurumi, T. Tanaka, and H. Moriwaki
(-)-Epigallocatechin Gallate Suppresses Azoxymethane-Induced Colonic Premalignant Lesions in Male C57BL/KsJ-db/db Mice
Cancer Prevention Research, September 1, 2008; 1(4): 298 - 304.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Qin, H.-G. Chen, Q. Yan, M. Deng, J. Liu, S. Doerge, W. Ma, Z. Dong, and D. Wan-Cheng Li
Protein Phosphatase-2A Is a Target of Epigallocatechin-3-Gallate and Modulates p53-Bak Apoptotic Pathway
Cancer Res., June 1, 2008; 68(11): 4150 - 4162.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
J.-S. Choi, Y.-J. Choi, S.-Y. Shin, J. Li, S.-W. Kang, J.-Y. Bae, D. S. Kim, G.-E. Ji, J.-S. Kang, and Y.-H. Kang
Dietary Flavonoids Differentially Reduce Oxidized LDL-Induced Apoptosis in Human Endothelial Cells: Role of MAPK- and JAK/STAT-Signaling
J. Nutr., June 1, 2008; 138(6): 983 - 990.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
C. E. Isaacs, G. Y. Wen, W. Xu, J. H. Jia, L. Rohan, C. Corbo, V. Di Maggio, E. C. Jenkins Jr., and S. Hillier
Epigallocatechin Gallate Inactivates Clinical Isolates of Herpes Simplex Virus
Antimicrob. Agents Chemother., March 1, 2008; 52(3): 962 - 970.
[Abstract] [Full Text] [PDF]


Home page
Bioscience HorizonsHome page
S. Brierley-Hobson
Binding of (-)-epigallocatechin-3-gallate to the Hsp70 ATPase domain may promote apoptosis in colorectal cancer
Bioscience Horizons, March 1, 2008; 1(1): 9 - 18.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Adachi, T. Nagao, H. I. Ingolfsson, F. R. Maxfield, O. S. Andersen, L. Kopelovich, and I. B. Weinstein
The Inhibitory Effect of (-)-Epigallocatechin Gallate on Activation of the Epidermal Growth Factor Receptor Is Associated with Altered Lipid Order in HT29 Colon Cancer Cells
Cancer Res., July 1, 2007; 67(13): 6493 - 6501.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
R. A. Lubet, C. S. Yang, M.-J. Lee, Y. Hara, I. M. Kapetanovic, J. A. Crowell, V. E. Steele, M. M. Juliana, and C. J. Grubbs
Preventive effects of Polyphenon E on urinary bladder and mammary cancers in rats and correlations with serum and urine levels of tea polyphenols
Mol. Cancer Ther., July 1, 2007; 6(7): 2022 - 2028.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
F. Spinella, L. Rosano, V. Di Castro, S. Decandia, A. Albini, M. R. Nicotra, P. G. Natali, and A. Bagnato
Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma.
Mol. Cancer Ther., June 1, 2006; 5(6): 1483 - 1492.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
Q. Zhang, X. Tang, Q. Lu, Z. Zhang, J. Rao, and A. D. Le
Green tea extract and (-)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1{alpha} protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells
Mol. Cancer Ther., May 1, 2006; 5(5): 1227 - 1238.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. Khan, F. Afaq, M. Saleem, N. Ahmad, and H. Mukhtar
Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate.
Cancer Res., March 1, 2006; 66(5): 2500 - 2505.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Z. Hou, S. Sang, H. You, M.-J. Lee, J. Hong, K.-V. Chin, and C. S. Yang
Mechanism of Action of (-)-Epigallocatechin-3-Gallate: Auto-oxidation-Dependent Inactivation of Epidermal Growth Factor Receptor and Direct Effects on Growth Inhibition in Human Esophageal Cancer KYSE 150 Cells
Cancer Res., September 1, 2005; 65(17): 8049 - 8056.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.